Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | ALPINE results: zanubrutinib vs. ibrutinib in CLL

The ALPINE study (NCT03734016) investigated zanubrutinib vs. ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL). Here, Constantine Tam, MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the results thus far from the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.